ArticleNeurosciences (Riyadh, Saudi Arabia)2026
Vagal Nerve Stimulation as Therapy for Drug-Resistant Epilepsy: A Tertiary Hospital Experience of Outcomes and Efficacy in King Abdullah Medical City.
Article in Neurosciences (Riyadh, Saudi Arabia), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine the efficacy and safety of vagus nerve stimulation (VNS) for reducing the frequency of seizures and complications in drug-resistant epilepsy. Methods: This was a retrospective case series study conducted in King Abdullah Medical City from January 2015 to December 2021 hospital record. All patients undergoing VNS were enrolled according to inclusion and exclusion criteria. Patients were followed up for 12 months, and the seizure frequency and number of epileptic drugs used were evaluated. A paired sample t-test was applied to compare the outcome variables considering Results: Among 9 enrolled patients, four were females, and five were males. The mean age of the patients was 23.9 ± 10.8 years. The average number of drugs used before VNS was 3, while it was 2 after VNS. However, a statistically significant (p = 0.08) reduction was not achieved. The mean seizure frequency before and after VNS was 14.4 ± 4.0 and 2.2 ± 3.2 at the 12-month follow-up visit (p < 0.05). The seizure frequency was statistically significantly reduced since the Conclusion: The VNS is a safe and effective adjuvant therapy for reducing the frequency of seizures in patients with drug-resistant epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.